Search Results - "Kieseier, Bernd C"

Assessing walking disability in multiple sclerosis by Kieseier, Bernd C., Pozzilli, Carlo

“…Most patients with multiple sclerosis (MS) eventually experience walking disability. The objective of this review was to evaluate the clinical utility of…”
Get full text

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study by Calabresi, Peter A, Prof, Kieseier, Bernd C, MD, Arnold, Douglas L, Prof, Balcer, Laura J, Prof, Boyko, Alexey, Prof, Pelletier, Jean, MD, Liu, Shifang, PhD, Zhu, Ying, PhD, Seddighzadeh, Ali, MD, Hung, Serena, MD, Deykin, Aaron, MD

“…Summary Background Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less…”
Get full text

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis by De Stefano, Nicola, Airas, Laura, Grigoriadis, Nikolaos, Mattle, Heinrich P., O’Riordan, Jonathan, Oreja-Guevara, Celia, Sellebjerg, Finn, Stankoff, Bruno, Walczak, Agata, Wiendl, Heinz, Kieseier, Bernd C.

“…Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative pathology. Axonal loss and neurodegeneration occurs early in the…”
Get full text

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy by Klehmet, Juliane, Tackenberg, Björn, Haas, Judith, Kieseier, Bernd C

“…Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often affecting patient's ability…”
Get full text

Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy by Merkies, Ingemar S J, Kieseier, Bernd C

“…In the clinical evaluation of patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), scant attention…”
Get more information

Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model by Stangel, Martin, Penner, Iris Katharina, Kallmann, Boris A., Lukas, Carsten, Kieseier, Bernd C.

“…Objective: The introduction of new and potent therapies for the treatment of relapsing remitting multiple sclerosis (MS) has increased the desire for…”
Get full text

Schwann cells promote post-traumatic nerve inflammation and neuropathic pain through MHC class II by Hartlehnert, Maike, Derksen, Angelika, Hagenacker, Tim, Kindermann, David, Schäfers, Maria, Pawlak, Mathias, Kieseier, Bernd C., Meyer zu Horste, Gerd

“…The activation of T helper cells requires antigens to be exposed on the surface of antigen presenting cells (APCs) via MHC class II (MHC-II) molecules…”
Get full text

Guillain-Barré syndrome after exposure to influenza virus by Lehmann, Helmar C, MD, Hartung, Hans-Peter, Prof, Kieseier, Bernd C, Prof, Hughes, Richard AC, Prof

“…Summary Guillain-Barré syndrome (GBS) is an acute, acquired, monophasic autoimmune disorder of peripheral nerves that develops in susceptible individuals after…”
Get full text

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial by Kappos, Ludwig, Prof, Arnold, Douglas L, Prof, Bar-Or, Amit, Prof, Camm, John, Prof, Derfuss, Tobias, Prof, Kieseier, Bernd C, Prof, Sprenger, Till, Prof, Greenough, Kristin, MSc, Ni, Pingping, PhD, Harada, Tomohiko, MD

“…Summary Background Patients with multiple sclerosis, a chronic inflammatory demyelinating disease of the central nervous system with autoimmune pathogenesis,…”
Get full text

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients by Schwab, Nicholas, Schneider-Hohendorf, Tilman, Posevitz, Vilmos, Breuer, Johanna, Göbel, Kerstin, Windhagen, Susanne, Brochet, Bruno, Vermersch, Patrick, Lebrun-Frenay, Christine, Posevitz-Fejfár, Anita, Capra, Ruggero, Imberti, Luisa, Straeten, Vera, Haas, Juergen, Wildemann, Brigitte, Havla, Joachim, Kümpfel, Tania, Meinl, Ingrid, Niessen, Kyle, Goelz, Susan, Kleinschnitz, Christoph, Warnke, Clemens, Buck, Dorothea, Gold, Ralf, Kieseier, Bernd C., Meuth, Sven G., Foley, John, Chan, Andrew, Brassat, David, Wiendl, Heinz

“…OBJECTIVE:To find biomarkers identifying patients at risk for the development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment…”
Get full text

Corneal confocal microscopy differentiates inflammatory from diabetic neuropathy by Fleischer, Michael, Lee, Inn, Erdlenbruch, Friedrich, Hinrichs, Lena, Petropoulos, Ioannis N, Malik, Rayaz A, Hartung, Hans-Peter, Kieseier, Bernd C, Kleinschnitz, Christoph, Stettner, Mark

“…Immune-mediated neuropathies, such as chronic inflammatory demyelinating polyneuropathy (CIDP) are treatable neuropathies. Among individuals with diabetic…”
Get full text

Novel pathomechanisms in inflammatory neuropathies by Schafflick, David, Kieseier, Bernd C, Wiendl, Heinz, Meyer Zu Horste, Gerd

“…Inflammatory neuropathies are rare autoimmune-mediated disorders affecting the peripheral nervous system. Considerable progress has recently been made in…”
Get full text

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod by Jander, Sebastian, Turowski, Bernd, Kieseier, Bernd C, Hartung, Hans-Peter

“…In this report we describe a multiple sclerosis patient who developed a relapse with magnetic resonance imaging (MRI) features of tumefactive demyelination…”
Get full text

Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) by Mowry, Ellen M, Bermel, Robert A, Williams, James R, Benzinger, Tammie L S, de Moor, Carl, Fisher, Elizabeth, Hersh, Carrie M, Hyland, Megan H, Izbudak, Izlem, Jones, Stephen E, Kieseier, Bernd C, Kitzler, Hagen H, Krupp, Lauren, Lui, Yvonne W, Montalban, Xavier, Naismith, Robert T, Nicholas, Jacqueline A, Pellegrini, Fabio, Rovira, Alex, Schulze, Maximilian, Tackenberg, Björn, Tintore, Mar, Tivarus, Madalina E, Ziemssen, Tjalf, Rudick, Richard A

“…Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is the first example of a learning health system in multiple sclerosis (MS)…”
Get full text

Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics by Derksen, Angelika, Ritter, Christian, Athar, Parveen, Kieseier, Bernd C., Mancias, Pedro, Hartung, Hans-Peter, Sheikh, Kazim A., Lehmann, Helmar C.

“…ABSTRACT Introduction: Electrodiagnostic features of demyelination are essential for establishing the diagnosis in demyelinating subtypes of Guillain‐Barré…”
Get full text

Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study by Kira, Jun-ichi, Nakahara, Jin, Sazonov, Denis V, Kurosawa, Takayoshi, Tsumiyama, Isao, Willi, Roman, Zalesak, Martin, Pingili, Ratnakar, Häring, Dieter A, Ramanathan, Krishnan, Kieseier, Bernd C, Merschhemke, Martin, Su, Wendy, Saida, Takahiko

“…Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can…”
Get full text

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy by Warnke, Clemens, von Geldern, Gloria, Markwerth, Philipp, Dehmel, Thomas, Hoepner, Robert, Gold, Ralf, Pawlita, Michael, Kümpfel, Tania, Mäurer, Mathias, Stangel, Martin, Wegner, Florian, Hohlfeld, Reinhard, Straeten, Vera, Limmroth, Volker, Weber, Thomas, Hermsen, Derik, Kleinschnitz, Christoph, Hartung, Hans-Peter, Wattjes, Mike P., Svenningson, Anders, Major, Eugene, Olsson, Tomas, Kieseier, Bernd C., Adams, Ortwin

“…Objective Progressive multifocal leukoencephalopathy (PML), caused by JC virus (JCV), can occur in patients receiving natalizumab for multiple sclerosis (MS)…”
Get full text

Lysophosphatidic acid propagates post-injury Schwann cell dedifferentiation through LPA1 signaling by Szepanowski, Fabian, Szepanowski, Leon-Phillip, Mausberg, Anne K., Kleinschnitz, Christoph, Kieseier, Bernd C., Stettner, Mark

“…•Lysophosphatidic acid (LPA) induces demyelination and Schwann cell (SC) dedifferentiation in DRG cultures.•LPA mediated effects can be blocked by a LPA1…”
Get full text

A critical appraisal of treatment decisions in multiple sclerosis—old versus new by Kieseier, Bernd C., Stüve, Olaf

“…A number of established therapies are available for multiple sclerosis (MS), but the advent of numerous novel therapies has meant that treatment decisions for…”
Get full text

Atacicept: targeting B cells in multiple sclerosis by Hartung, Hans-Peter, Kieseier, Bernd C.

“…Multiple sclerosis (MS) has traditionally been considered to be a T-cell-mediated disease. However, there is an increasing body of evidence for the involvement…”
Get full text